医学
利福昔明
肝性脑病
乳果糖
重症监护医学
肝硬化
脑病
高氨血症
生活质量(医疗保健)
内科学
生物
微生物学
护理部
抗生素
作者
Bryan D. Badal,Jasmohan S. Bajaj
标识
DOI:10.1016/j.mcna.2023.01.003
摘要
Hepatic encephalopathy (HE) is brain dysfunction secondary to liver insufficiency or portosystemic shunting. HE is a major burden on patients and caregivers, impairs quality of life and is associated with higher mortality. Overt HE is a clinical diagnosis while Covert HE, needs specialized diagnostic strategies. Mainstay of treatment of HE is nonabsorbable disaccharides such as lactulose as well as rifaximin; however, investigational therapies are discussed in this review. Better tools are needed to prognosticate which patients will go on to develop HE but microbiome and metabolomic-driven strategies are promising. Here we review methods to prevent the HE development and admissions.
科研通智能强力驱动
Strongly Powered by AbleSci AI